Transfer

In collaboration with Helmholtz Munich, Medigene is expanding its portfolio of costimulatory switch proteins in the field of cancer immunotherapy. By expanding the license field, these specialized proteins, initially developed by Helmholtz Munich,…

The Life Science Factory incubator initiated by Sartorius in Göttingen and the top biomedical research center Helmholtz Munich are entering into a strategic partnership to support spin-offs in the life sciences. Within this framework, the Life…

Bayerischer Medizingipfel im TranslaTUM am 17.7.2023

"M1 - Munich Medicine Alliance" established as a strategic alliance for excellence in healthcare in Munich.

The Helmholtz Pioneer Campus was officially inaugurated today under the slogan "ENGINEERING THE FUTURE OF MEDICINE". Commissioning this new state-of-the-art research facility is a significant milestone for young talents in medical research and…

Prof. Reinhard Zeidler about hope in the fight against glioblastoma, the most common and malignant form of brain tumor and how he accelerates the development of antibodies into application.

Medical concept of cancer. 3d illustration of T cells or cancer cells.

Helmholtz Munich and Medigene AG expand their partnership in order to further discover and develop T-cell immunotherapies for solid tumors. Medigene acquired from Helmholtz Munich the exclusive, worldwide rights to the CD40L-CD28 Costimulatory Switch…

Transfer

News

Medigene Expands Helmholtz Munich IP Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types

Life Science Factory to Open a New Location at Helmholtz Munich in 2024

Helmholtz Munich strengthens healthcare excellence in Munich through strategic alliance

The Future of Medicine: Helmholtz Munich Opens Innovation Campus

Targeted Antibody Therapy Against Brain Tumor Glioblastoma

Helmholtz Munich partners with Medigene to accelerate Tumor Therapy